New Radiomedicine Technology
Chengdu
About New Radiomedicine Technology
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting. In April 2016, the company was founded by three co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy. The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $330.6M
- Funding stage: Late Stage Venture
- Last round: Series E (Apr 2026)
- Website: nrtmedtech.com
- Phone: 028-8244 8001
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/new-radiomedicine-technology-91594 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.